Having signed a partnership with CERITD, the French Centre for Studies and Research for the Intensification of Diabetes Treatment, Air Liquide is strengthening its position in home healthcare for patients with diabetes. Air Liquide has also acquired an equity stake in 'Diabeloop', the French start-up that is developing an electronic artificial pancreas. With this new collaboration, Air Liquide continues the approach initiated by CERITD based on cooperation between hospital teams and homecare nurses.
At the request of physicians, nurses will be able to help provide even more personalized follow-up for patients with diabetes treated at home, such as adjusting the treatment in accordance with a strict protocol.
In addition, to increase its level of expertise in the field of diabetes and support innovation, Air Liquide has acquired an equity stake via ALIAD, the Group’s venture capital investment arm, in the French start-up Diabeloop, which is developing its own artificial pancreas. Founded by CERITD’s diabetes specialists, in partnership with the CEA Leti, Diabeloop is designing an electronic artificial pancreas composed of an insulin pump in the form of a patch and a glucose sensor both connected. Driven by an algorithm, this system will enable to automate the delivery of insulin and thus reproduce the functions of the defective pancreas.
In practice, using the data collected by the continuous glucose sensor, the algorithm determines the right dose of insulin, which is then delivered in real time via the insulin pump in order to improve patient glucose regulation.
This technology will help improve the daily life of patients with type 1 diabetes by partially automating the management of this disease. The investment made by Air Liquide in Diabeloop confirms the Group’s commitment to digital technologies and healthcare, in the aim of helping patients achieve a better quality of life and care.
François Jackow, member of the Air Liquide group’s Executive Committee, supervising the Healthcare activities, said: "The partnership with CERITD, a leading research centre for diabetes treatment, and investments in innovative projects such as Diabeloop's electronic artificial pancreas, are in line with the development strategy of Air Liquide's Home Healthcare activity. By relying on innovation ecosystems, Air Liquide is contributing to advances in home care for patients with chronic illnesses."